|
Match
|
Document |
Document Title |
|
|
5413792 |
Mucoadhesive polysiloxane paste-like base and preparation
The specification describes and claims a paste-like preparation comprising (A) a paste-like base comprising a polyorganosiloxane and a water-soluble polymeric material which are preferably present...
|
|
|
5413797 |
Controlled release ACTH containing microspheres
ACTH polymeric controlled release systems are described wherein the ACTH retains good biological activity and is released over an extended period of time following administration by injection. In...
|
|
|
5385734 |
Horseradish preparation for the treatment of nasal and sinus dysfunction
A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the...
|
|
|
5376386 |
Aerosol carriers
Pharmaceutical excipients useful in dry powder inhalents comprise particles having a rugosity (measured by air permeametry) of less than 1.75. The use of these carriers increases the amount of drug...
|
|
|
5364634 |
Controlled-release PH sensitive capsule and adhesive system and method
A capsule and method for delivery for an active ingredient in the oral cavity that has a pH sensitive encapsulant shell and is associated with an adhesive. The pH sensitive shell dissolves at a pH...
|
|
|
5362495 |
Insert material for widening the gingival sulcus
The present invention has for its object an insert material used for widening the gingival sulcus, substantially without bleeding or oozing, particularly in order to make a cast for a dental...
|
|
|
5352448 |
Oral administration of antigens
An oral vaccine formulation is provided for stimulation of an immune response in gut-associated lymphoid tissues. The formulation comprises an enzymatically degradable antigen in a hydrogel matrix....
|
|
|
5348746 |
Method for administering drug
A dosage form is disclosed comprising means for lessening the tackiness and/or irritation of the components of the dosage form to mucosal tissue. The dosage form provides means for forming in the...
|
|
|
5324521 |
Systems for transdermal administration of medicaments
A non-adhesive matrix for use as a dosage form in the transdermal administration of a medicament to a mammal comprises a porous, non-adhesive, absorbent perforate solid support having absorbed...
|
|
|
5324520 |
Intragingival delivery systems for treatment of periodontal disease
A polymeric controlled delivery system is provided for use in treating periodontal disease. The delivery system in a variety of forms is placed directly in the infected gingival tissue where the...
|
|
|
5304377 |
Prolonged release preparation and polymers thereof
A polymer for a prolonged release preparation which comprises (A) a polylactic acid and (B) a copolymer of glycolic acid and a hydroxycarboxylic acid of general formula ##STR1## wherein R...
|
|
|
5296228 |
Compositions for controlled delivery of pharmaceutical compounds
Sustained release pharmaceutical compound delivery compositions and methods for their production are disclosed wherein ion exchange resin particles are loaded with releasably bound pharmaceutical...
|
|
|
5292513 |
Method for nonspecific cellular immune stimulation
A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response...
|
|
|
5288498 |
Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates...
|
|
|
5288497 |
Compositions of oral dissolvable medicaments
Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates...
|
|
|
5284656 |
Pulmonary administration of granulocyte colony stimulating factor
Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary...
|
|
|
5281711 |
(S)-1-[10-chloro-6,7-dihydro-4-oxo-3-phenyl-4H-benzo[a]quino-lizin-1-yl) carbonyl]-3-ethoxypyrrolidine
The compound (S)-1-[(10-chloro-6,7-dihydro-4-oxo-3-phenyl-4H-benzo[a]quin
o-lizin-1-yl)c arbonyl]-3-ethoxypyrrolidine of the formula ##STR1## which has valuable pharmacological properties, is...
|
|
|
5275820 |
Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
Sustained release pharmaceutical compound delivery compositions and methods for their production are disclosed wherein ion exchange resin particles are loaded with releasably bound pharmaceutical...
|
|
|
5262164 |
Sustained release compositions for treating periodontal disease
This invention relates to compositions and methods for treating diseases of the oral cavity in humans and lower animals using a glycerol monooleate gel for releasing drugs in the oral cavity.
|
|
|
5254346 |
Occlusive body for administering a physiologically active substance
An occlusive body such as a patch, pad or bandage is provided which incorporates a reservoir (5) containing a physiologically active substance, the reservoir incorporating a membrane permeable to...
|
|
|
5248504 |
Method of treatment for nasal and sinus dysfunction
A method of treatment for nasal and sinus dysfunction is disclosed comprising topically applying a horseradish, sinigrin or allyl isothiocyanate preparation to affected mucosa. Preparations for the...
|
|
|
5244663 |
Therapeutic method against allergy
Allergens are contained in strictly controlled and reproducible amounts on solid supports to provide a progressive release of the allergen perlingually and sublingually. The compositions are...
|
|
|
5238683 |
Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
An aerosol preparation of reduced glutathione (GSH) is provided to augment the level of GSH in the lungs. Treatment of pulmonary conditions, where reduced level of GSH is found, by the aerosol...
|
|
|
5230895 |
Sustained released delivery system for use in the periodontal pocket
An in vivo method is described for treating a subject for periodontal disease by placing a mixture of a glyceride composition and a therapeutic agent in the periodontal pocket of subject such that...
|
|
|
5225196 |
Bioadhesive compositions and methods of treatment therewith
A controlled release treatment composition method of use are disclosed. The composition includes a bioadhesive and an effective amount of a treating agent. The bioadhesive is a water-swellable, but...
|
|
|
5215739 |
Spray gel base and spray gel preparation using thereof
A spray gel base having an excellent spread-stick property, which is prepared by thickening a 0.2-1.5 % by weight aqueous solution of carboxyvinyl polymer with a water-soluble basic substance,...
|
|
|
5204108 |
Transmucosal formulations of low molecular weight peptide drugs
A drug delivery composition comprising a plurality of microspheres and active drug associated with each microsphere, the drug being for systemic delivery and having a maximum molecular weight of...
|
|
|
5178873 |
Essential fatty acid treatment
A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is...
|
|
|
5164195 |
Method of oral delivery with an adherent controlled-release salt sensitive capsule
A salt sensitive capsule has been developed which dissolves in the mouth and releases the encapsulated internal ingredient(s). The outer salt sensitive shell maintains its integrity when kept at a...
|
|
|
5158775 |
Aerosols of pyrido [1,2-a]pyrimidine compounds
A suspension type aerosol inhalations containing (a) 0.015 to 5.00% (w/w) of a pyrido[1,2-a]pyrimidine compound of the formula: ##STR1## where R is a n-propyl or allyl group, A is a tetrazolyl or...
|
|
|
5147648 |
Method of improving the adhesiveness of gels to mucosae
For improving the adherence of gels to the mucous membranes, one applies separately to the same area of a mucous membrane two components capable of forming together a gel, for example a metallic...
|
|
|
5135753 |
Method and therapeutic system for smoking cessation
A method for smoking cessation therapy is described that utilizes transdermal nicotine delivery for obtaining base-line coupled with buccal administration of nicotine to satisfy transient craving.
|
|
|
5130137 |
Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
This invention is directed to a delivery system and a method useful for the treatment of benign ovarian secretory disorders in female mammals by administering an LHRH composition. The method...
|
|
|
5116619 |
Vaginal progesterone tablet
A vaginal progesterone suppository is provided in the form of a tablet which delivers biologically effective amounts of progesterone for at least about 48 hours, and blood amounts above basal...
|
|
|
5114718 |
Sustained release compositions for treating periodontol disease
This invention relates to devices/compositions and methods for treating diseases of the oral cavity in humans and lower animals using non-biodegradable devices/compositions which are biocompatible...
|
|
|
5112804 |
Pharmaceutical composition and method of intranasal administration
A composition and method for nasal administration of pharmaceuticals utilizes glycyrrhetinic acid as an absorption enhancer. The composition comprises an effective amount of the pharmaceutically...
|
|
|
5112617 |
Method for controlling cold symptoms
A composition for control of cold symptoms comprising 80-90% of 8% strength hydrogen peroxide, 3-7% hammermelis water 3-7% orange flower water, 0.1-0.5% magnesium carbonate, 0.05-0.15% almond...
|
|
|
5110605 |
Calcium polycarbophil-alginate controlled release composition and method
A polymeric complex composition comprising a reaction complex formed by the interaction of a polycarbophil component with alginic acid or a salt thereof, said interaction being performed in the...
|
|
|
5093127 |
Preparation of FR115224 substrate for parenteral administration
A cyclic peptide designated FR115224, administered parenterally in a cyclodextrin carrier, which exhibits antiallergic activity.
|
|
|
5077284 |
Use of dehydroepiandrosterone to improve immune response
The steroid hormone dehydroepiandrosterone (DHEA), when administered by feeding or by subcutaneous injection, significantly improves the host response to viral infection. Experimental animal data...
|
|
|
5075112 |
Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
Method of, and dosage unit for, inhibiting angiogenesis in an aminal having an intestinal wall by administering to the animal, orally or anally, an effective amount of shark cartilage, particularly...
|
|
|
5073374 |
Fast dissolving buccal tablet
A fast dissolving buccal tablet for administering a medicament includes the active ingredient, a lubricant and a water soluble sugar, such as sorbitol, combined such that the buccal tablet...
|
|
|
5071655 |
Pharmaceutical combination for treatment of bone-wasting diseases
A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically...
|
|
|
5068107 |
Polymeric orthodontic members and orthodontic treatment method
An improved elastic orthodontic member and treatment method for preventing and treating certain dental diseases often associated with or increased by normal orthodontic treatment. The orthodontic...
|
|
|
5063061 |
Aqueous preparation of pyrido(1,2-a)pyrimidine compound
An aqueous preparation comprising of 0.1 to 0.3% (W/V) of a pyrido[1,2-a]pyrimidine compound represented by the following formula: ##STR1## wherein R represents an n-propyl or allyl group, A...
|
|
|
5061493 |
Galenical forms of corticoids for administration perlingually and sublingually and process for their preparation
In these new galenical forms the corticoid is contained, in strictly controlled and reproducible amounts, in solid supports provided for an extended release of the active ingredient perlingually...
|
|
|
5049389 |
Novel liposome composition for the treatment of interstitial lung diseases
A non-conventional lipid particle formulation for the sustained release and delivery of steroids into deep lung is disclosed. The formulation provides prolonged release of the drug, improved...
|
|
|
5047244 |
Mucoadhesive carrier for delivery of therapeutical agent
A mucoadhesive carried suitable for a therapeutic agent is disclosed. This carrier allows controlled release of the therapeutic agent via mucosal tissue. The mucoadhesive carrier comprises a...
|
|
|
5047418 |
Method of stimulating histamine H.sub.3 -receptors
A pharmaceutical composition is described which comprises a pharmaceutically acceptable carrier and a compound of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof wherein X...
|
|
|
5039526 |
Buccal lozenge for fluoride ion medication
A buccal lozenge medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge containing from 20 to 100 milligrams of sodium...
|